pyrazines has been researched along with Exanthema in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sriwijitalai, W; Wiwanitkit, V | 1 |
| Andreoli, A; Briere, J; Cavelier Balloy, B; Petit, A; Thomas, M | 1 |
| Baltaci, M; Böckle, BC; Sepp, NT; Weyrer, W | 1 |
| Aki, SZ; Erdem, O; Ozkurt, ZN; Sucak, GT; Yağci, M | 1 |
| Mahé, E; Sigal, ML; Sin, C | 1 |
| Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A | 1 |
| Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P | 1 |
| Betlloch, I; Botella, C; Lucas, A; Mataix, J; Villarrubia, B | 1 |
| Choi, L; Denis, LJ; Eskens, FA; Foekens, JA; Harris, AL; Levitt, NC; Nakajima, M; O'Byrne, KJ; Owen, SJ; Propper, DJ; Steward, WP; Talbot, DC; Verweij, J; Wilner, S; Wood, JM | 1 |
1 trial(s) available for pyrazines and Exanthema
| Article | Year |
|---|---|
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Female; Humans; Hydroxamic Acids; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Nausea; Neoplasms; Protease Inhibitors; Pyrazines; Sulfonamides; Treatment Outcome | 2001 |
8 other study(ies) available for pyrazines and Exanthema
| Article | Year |
|---|---|
COVID-19 and favipiravir induce cutaneous adverse reactions: a difficulty in clinical dermatology practice.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Dermatology; Exanthema; Humans; Pyrazines | 2022 |
[Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration].
Topics: Antigens, CD; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Ki-1 Antigen; Lymphocytes; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Skin Diseases | 2009 |
Bortezomib-induced lupus erythematosus tumidus.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Lupus Erythematosus, Cutaneous; Pyrazines | 2009 |
Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2009 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
Topics: Acute Kidney Injury; Aged; Back; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ear; Edema; Eosinophilia; Exanthema; Female; Glucocorticoids; Humans; Prednisone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Skin lesions induced by bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy | 2005 |
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome | 2007 |
Bortezomib-associated rash: a new recognizable and avoidable side-effect.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2007 |